Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model
暂无分享,去创建一个
Paul S. Aisen | Nobuhisa Iwata | Mark P. Mattson | Takaomi C. Saido | M. Mattson | P. Aisen | W. Klein | F. LaFerla | C. Hirata-Fukae | Y. Matsuoka | K. Duff | T. Saido | N. Iwata | T. Niikura | G. Rebeck | H. Hoe | Frank M. LaFerla | Mohamed R. Mughal | Hyang-Sook Hoe | A. Gray | William L. Klein | Yasuji Matsuoka | S. Minami | Takako Niikura | Chiho Hirata-Fukae | Hui-Fang Li | Audrey J. Gray | S. Sakura Minami | Katsuyoshi Hamada | Fang Hua | Hiroe Tsukagoshi-Nagai | Yuko Horikoshi-Sakuraba | Mohamed Mughal | G. William Rebeck | Karen E. Duff | Katsuyoshi Hamada | Fang Hua | Hiroe Tsukagoshi-Nagai | Yuko Horikoshi-Sakuraba | Hui-Fang Li | P. S. Aisen | Hui Fang Li | Yasuji Matsuoka | Hui Fang Li
[1] E. Bigio,et al. Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.
[2] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[3] Wen-Lang Lin,et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.
[4] H. Braak,et al. Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.
[5] C. Masters,et al. Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease , 2002 .
[6] P. Davies,et al. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. L. François,et al. Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease , 2001, Neuroscience.
[8] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[9] Jason Eriksen,et al. A decade of modeling Alzheimer's disease in transgenic mice. , 2006, Trends in genetics : TIG.
[10] J. Trojanowski,et al. Epitopes that span the tau molecule are shared with paired helical filaments , 1988, Neuron.
[11] L. Hersh,et al. Estrogen regulates neprilysin activity in rat brain , 2004, Neuroscience Letters.
[12] Anthony Gamst,et al. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .
[13] F. Bian,et al. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. , 2001, The American journal of pathology.
[14] T. Saido,et al. Region‐specific reduction of Aβ‐degrading endopeptidase, neprilysin, in mouse hippocampus upon aging , 2002, Journal of neuroscience research.
[15] F. LaFerla,et al. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. , 2007, The American journal of pathology.
[16] B. Hyman,et al. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.
[17] S. Paul,et al. Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease. , 2005, Endocrinology.
[18] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[19] K. Ashe,et al. Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.
[20] B L Miller,et al. Estrogen for Alzheimer’s disease in women , 2000, Neurology.
[21] D. Selkoe,et al. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.
[22] P. Aisen,et al. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. , 2004, Biochemical and biophysical research communications.
[23] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[24] P. Wong,et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.
[25] J. Hardy,et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.
[26] E. Mandelkow,et al. The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region. , 1992, The EMBO journal.
[27] David W. Smith,et al. Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor , 2005, Journal of Pharmacology and Experimental Therapeutics.
[28] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[29] P. Wong,et al. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild‐type mice 2 , 2006, Journal of neurochemistry.
[30] R. Brookmeyer,et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.
[31] J. Lafrancois,et al. Modulation of Aβ peptides by estrogen in mouse models , 2002, Journal of neurochemistry.
[32] L. Hy,et al. Prevalence of AD among whites , 2000, Neurology.
[33] J. Ávila,et al. Estradiol Prevents Neural Tau Hyperphosphorylation Characteristic of Alzheimer's Disease , 2005, Annals of the New York Academy of Sciences.
[34] L. Mucke,et al. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.
[35] J. Trojanowski,et al. Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] N. Takata,et al. Hippocampal synthesis of estrogens and androgens which are paracrine modulators of synaptic plasticity: Synaptocrinology , 2006, Neuroscience.
[37] Yaakov Stern,et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.
[38] P. Aisen,et al. A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.
[39] I. McDowell,et al. Alzheimer’s disease: Insights from epidemiology , 2001, Aging.
[40] Miles W. Miller,et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice , 1999, Nature Medicine.
[41] B. Hyman,et al. The Neuropathological Diagnosis of Alzheimer’s Disease: Clinical-Pathological Studies , 1997, Neurobiology of Aging.
[42] R. Berry,et al. β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis , 2007, The Journal of Neuroscience.
[43] Ilana S. Hairston,et al. Environmental Enrichment Reduces Aβ Levels and Amyloid Deposition in Transgenic Mice , 2005, Cell.
[44] J. Hardy,et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.
[45] Brenda L Plassman,et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.
[46] H C Liu,et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD , 2000, Neurology.
[47] R. Nelson,et al. Anesthesia Leads to Tau Hyperphosphorylation through Inhibition of Phosphatase Activity by Hypothermia , 2007, The Journal of Neuroscience.
[48] David H. Cribbs,et al. Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.
[49] B. Hyman,et al. Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.
[50] M. Higuchi,et al. Metabolism of amyloid-β peptide and Alzheimer's disease , 2005 .
[51] G. Lindwall,et al. Phosphorylation affects the ability of tau protein to promote microtubule assembly. , 1984, The Journal of biological chemistry.
[52] C. Lemere,et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.
[53] S. Gandy,et al. Post-menopausal estrogen deprivation and Alzheimer's disease , 2000, Experimental Gerontology.
[54] R Brookmeyer,et al. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.
[55] E G Tangalos,et al. Postmenopausal estrogen replacement therapy and risk of AD , 1999, Neurology.
[56] R. Nitsch,et al. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.
[57] Yama Akbari,et al. Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders , 2005, Neurobiology of Aging.
[58] M. Mattson,et al. Deglycosylated anti‐amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration , 2007, The European journal of neuroscience.
[59] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.